Germany has today voted to ban medical cannabis flower from its statutory health insurance scheme, in a controversial move critics say will have an outsized impact on the ‘seriously ill’.
IM Cannabis IM Cannabis has become the latest major Israeli cannabis company to announce potential plans to depart the industry altogether and sell off its remaining assets.
Jazz Pharmaceuticals has rebuffed attempts by rival Teva Pharmaceuticals to legally disqualify its patent for Epidyolex, a cannabis-based drug worth hundreds of millions of dollars a year.
A NEW landmark study into the effects of cannabidiol (CBD) on psychosis is scheduled to be launched ‘later this year’.
WITH the fast-growing CBD sector tied up in a regulatory quagmire hundreds of transatlantic industry players face an uncertain future.
Akanda Akanda has enjoyed a sharp recovery in its share price this week, seeing its value return to levels not seen since October.
PRESS RELEASE JAZZ Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Epidyolex® (cannabidiol,100 mg/mL oral solution), developed by GW Pharmaceuticals (“GW”; now part of Jazz Pharmaceuticals plc), a world leader in discovering, developing and delivering regulatory approved cannabinoid-based medicines, has been recommended for reimbursement by National Institute for Health and Care Excellence (NICE) for adjunctive therapy…
NEW UK government data suggest that the number of NHS prescriptions for ‘licenced’ cannabis-based medicines could rise significantly this year.
